Fertility preservation by conservative approach in a primiparous woman with placental adherence

Authors

  • Lovline M. Dsouza St. Johns Medical College Hospital, Bangalore, Karnataka, India
  • Akshaya Murali St. Johns Medical College Hospital, Bangalore, Karnataka, India https://orcid.org/0000-0001-5836-7241
  • Annamma Thomas St. Johns Medical College Hospital, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20232970

Keywords:

Adherent placenta, Methotrexate, Post-partum complications

Abstract

Placenta accreta spectrum (PAS) describes a group of disorders in which all, or part of the placenta remains adherent to the uterine wall. Early identification of risk factors, accurate diagnosis and treatment in accordance with the resources available are essential and can help in reducing maternal morbidity and mortality. In the absence of risk factors, placental adherence is a rare entity, and conservative management becomes essential, especially in primiparous women to preserve future fertility. A primigravida in her late twenties presented in labour at 35 weeks of pregnancy to deliver a live baby of 2200 gm. The placenta did not separate with uterotonics and multiple attempts at manual removal of placenta under general anaesthesia. Medical management to conserve the uterus was decided, and two doses of methotrexate (50 mg) were given intramuscularly a week apart. Placental products were expelled after 2 months and the patient resumed her normal menses. She conceived spontaneously 8 months later. PAS is a possibility, though rare, in low-risk primigravidae and preparedness to confront such situations is of utmost importance. Intramuscular single dose or multiple dose methotrexate can be considered as a viable option in stable patients who wish to retain their fertility.

 

References

American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet Gynecol. 2018;132(6):e259-75.

Doumouchtsis SK, Arulkumaran S. The morbidly adherent placenta: an overview of management options. Acta Obstet Gynecol Scand. 2010;89(9):1126-33.

Shinde G, Kuhite H, Mirji S, Shingatgeri S. A Rare Case of Morbidly Adherent Placenta in a Primigravida. J South Asian Fed Obstet Gynaecol. 2018;10(4S1):351-4.

Placenta Accreta Spectrum. Available at: https://www.acog.org/en/clinical/clinical-guidance/obstetric-care-consensus/articles/2018/12/placenta-accreta-spectrum. Accessed on 22 January, 2023.

Sentilhes L, Kayem G, Chandraharan E, Palacios-Jaraquemada J, Jauniaux E, for the FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Conservative management. Int J Gynecol Obstet. 2018;140(3):291-8.

Kumari O, Gaurav A, Khoiwal K, Gupta A, Kapur D, Halder R et al. Incidentally diagnosed placenta accreta managed conservatively in a primigravida: case report and review of literature. Int J Reprod Contracept Obstet Gynecol. 2022;11(5):1588-91.

Mussalli GM, Shah J, Berck DJ, Elimian A, Tejani N, Manning FA. Placenta accreta and methotrexate therapy: three case reports. J Perinatol Off J Calif Perinat Assoc. 2000;20(5):331-4.

Tamate M, Matsuura M, Habata S, Akashi Y, Tanaka R, Ishioka S et al. Preservation of fertility and subsequent childbirth after methotrexate treatment of placenta percreta: a case report. J Med Case Reports. 2015;9(1):232.

Waheed K, Sarwar A, Ejaz S. Conservative management of placenta increta in a primigravida: A case report. JPMA J Pak Med Assoc. 2019;69(7):1049-51.

Rajkumar B, Kumar N, Srinivasan S. Placenta percreta in primigravida, an unsuspected situation. Int J Reprod Contracept Obstet Gynecol. 2014;3(1):239-41.

Downloads

Published

2023-09-28

Issue

Section

Case Reports